Company Profile
GeneDx Stock Price, News & Catalysts
- Ticker:
- WGS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
87.06 USD (+5.47%)
Close
Last updated: August 21, 2026
1.58B USD
Market cap
Why the stock is moving
As of Aug 21, 2026, WGS closed up 5.47% at $87.06. No new same-company headline was identified in the current news window.
Company overview
Business overview
GeneDx is a genomics diagnostics company focused on rare-disease testing, exome sequencing, and clinical genetics. Its business helps clinicians diagnose difficult genetic conditions more efficiently.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, GeneDx sits in molecular diagnostics and genomics.
Business Model Characteristics
The company depends on test adoption, reimbursement, and the expansion of genomic testing across clinical settings.
Position Within the Biotechnology Landscape
GeneDx is a diagnostics platform name whose stock is driven by adoption, reimbursement, and workflow scale.
Future catalysts
- GeneDx’s catalysts are exome and genome testing volumes, reimbursement, and whether the rare-disease diagnostics franchise keeps expanding. The next update matters because the company’s value is still tied to workflow adoption and test mix.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of GeneDx (WGS)?
GeneDx (WGS) most recently closed at 87.06 USD, a +5.47% move versus the previous session.
What is the market cap of GeneDx (WGS)?
GeneDx currently has a market capitalization of 1.58B USD on BioPharmSignal.
What does GeneDx do?
GeneDx is a genomics diagnostics company focused on rare-disease testing, exome sequencing, and clinical genetics. Its business helps clinicians diagnose difficult genetic conditions more efficiently.
On which exchange is WGS stock listed?
GeneDx (WGS) is associated with NASDAQ, United States, Biopharma.
What is GeneDx?
GeneDx’s catalysts are exome and genome testing volumes, reimbursement, and whether the rare-disease diagnostics franchise keeps expanding.
Which conditions is GeneDx targeting with GeneDx?
GeneDx is associated with genetic disease based on its company overview and current catalyst commentary.
How does GeneDx describe recent progress with GeneDx?
GeneDx’s catalysts are exome and genome testing volumes, reimbursement, and whether the rare-disease diagnostics franchise keeps expanding.
What future catalysts are investors watching for GeneDx?
GeneDx’s catalysts are exome and genome testing volumes, reimbursement, and whether the rare-disease diagnostics franchise keeps expanding. The next update matters because the company’s value is still tied to workflow adoption and test mix.